Joining as chief financial officer is Bob Goeltz. Bob was most recently chief financial officer of CytomX Therapeutics [NASDAQ: CTMX], where he joined prior to their going public, and executed a late-stage private offering and an initial public offering (IPO). Prior to that, Bob was a finance executive for more than 11 years at Amgen and Onyx Pharmaceuticals, an Amgen subsidiary. He also previously served as an audit manager at Ernst and Young. Bob holds an MBA from the UCLA Anderson School of Management.

Joining as general counsel is Tamara ("Tammy") L. Tompkins, JD. Tammy was most recently general counsel, chief administrative officer and operating partner at the $4 billion venture investing juggernaut Khosla Ventures, where she was responsible for legal, financial, IR, and operational/administrative matters and served on boards of several portfolio companies. Prior to that, Tammy was general counsel at Amyris where she helped navigate the company from inception through IPO. Previously, she practiced law at Morgan, Lewis & Bockius, as well as at Brobeck, Phleger & Harrison and Shearman & Sterling. Tammy holds a juris doctor degree from Georgetown University.

Joining as senior vice president of operations is Doug Rich. Doug was most recently senior vice president of operations at KYTHERA Biopharmaceuticals, responsible for the company's manufacturing, supply chain and quality. Prior to that, Doug was vice president of quality at Boeringer Ingelheim, and held leadership positions during his 18 years at Amgen, both within the quality organization and global operations. Doug holds an MBA from Pepperdine University.

"We continue to be incredibly fortunate in our ability to attract stellar talent that matches the level of promise of UNITY's mission to attack diseases of aging and fundamentally reshape human healthspan," said Keith Leonard, UNITY chairman and CEO. "These key additions already have had a major impact in driving this mission toward reality."

Departing the company from their interim positions are John Smither as chief financial officer and Keith Klein as general counsel, both former KYTHERA executives who have been helping grow and structure UNITY's efforts over the past 18 months. "We deeply appreciate all the work done by both John and Keith to help transition UNITY from a pure research effort into a well-integrated, platform biotech company," said Leonard. "Having access to such experienced talent in our early stages has been critical to our impressive progress."

About UNITY BiotechnologyUNITY Biotechnology is developing therapeutics that increase healthspan by preventing, halting, or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions such as osteoarthritis, atherosclerosis, eye diseases, and kidney disease. Backed by a group of visionary investors, UNITY's world-class management team has experience building companies and developing medicines together: the team has collectively moved more than 90 therapeutic candidates into human clinical trials and developed 13 FDA-approved medicines. UNITY's mission is to build a future in which it doesn't hurt to be old a future in which people stay healthy and mobile long into old age. More information is available at www.unitybiotechnology.com.